Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

This summary is generated by an algorithm. If you find any mistakes, let us know.

GenEdit Announces Series A Financing and Provides Research Update at TIDES 2021
GenEdit Announces Series A Financing and Provides Research Update at TIDES 2021
UN

Unicorn Nest news

GenEdit Announces Series A Financing and Provides Research Update at TIDES 2021

– GenEdit has closed a $26m Series A financing.
– New investors include Eli Lilly, KTB Network, Company K Partners, Korea Investment Partners, DAYLI Partners, KB Investment, IMM Investment, and TIMEFOLIO Asset Management.
– The funding will support the further development of GenEdit’s NanoGalaxy™ platform of non-viral, non-lipid polymer nanoparticles, and the selection for clinical development of therapeutic candidates targeting diseases of the nervous system.

Source
Orum Therapeutics Closes $84 Million Series B Financing to Advance Novel Targeted Protein Degrader Payloads into Clinical Trials for Cancer
Orum Therapeutics Closes $84 Million Series B Financing to Advance Novel Targeted Protein Degrader Payloads into Clinical Trials for Cancer
UN

Unicorn Nest news

Orum Therapeutics Closes $84 Million Series B Financing to Advance Novel Targeted Protein Degrader Payloads into Clinical Trials for Cancer

– Orum Therapeutics closed a $84m Series B financing.
– The financing was led by IMM Investment and joined by new investors (KDB Investment and Atinum, among others) and existing investors (Intervest and KB Investment, among others).
– Orum plans to use the proceeds to advance the Company’s lead therapeutic candidates into clinical trials, explore additional payload chemistries to develop additional payloads that modulate the ubiquitin pathway, and other general corporate purposes.
– The company has developed a new class of ADC payloads, called neoDegraders, to specifically degrade intracellular target proteins within cancer cells via the E3 ubiquitin ligase pathway.

Source
1 2 3 58 59 60
Crunchbase icon

Content report

The following text will be sent to our editors: